Wire · opportunities
Elevar wins FDA nod for bile duct cancer drug Lyrfigtu, a first for a Korean firm
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 September 2026 · Fusion42 review
Elevar Therapeutics has received FDA approval for Lyrfigtu (lirafugratinib), a bile duct cancer drug targeting FGFR2 gene fusion, marking the first novel cancer drug approval for a Korean company. The drug showed a 46% objective response rate in trials and has potential for further cancer types and combination therapies.
This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 21 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
You must prepare for new competition in FGFR2-targeting cancer drugs as Elevar's independent FDA approval sets a precedent for Korean biotechs expanding globally. Test your drug pipelines for next-gen precision medicine moves and partnership opportunities with Big Pharma combining therapies.
◆ Coverage
6 sources · first reported 21 Sep 2026 · latest 28 Sep 2026
◆ Related on Wire
◆ Topics